永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

香港特别行政区成立纪念日休市 06-30 15:59:10

0.540

+0.010

+1.89%

最高0.540	最低0.510	成交量12.20万
今开0.520	昨收0.530	日振幅5.66%
总市值3.34亿	流通市值3.34亿	总股本6.18亿
成交额6.35万	换手率0.02%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":0.54,"timestamp":1782806350483,"preClose":0.53,"halted":0,"volume":122000,"delay":0,"changeRate":0.018867924528301903,"floatShares":618000000,"shares":618000000,"eps":-0.4850562723030468,"marketStatus":"香港特别行政区成立纪念日休市","change":0.01,"latestTime":"06-30 15:59:10","open":0.52,"high":0.54,"low":0.51,"amount":63480,"amplitude":0.056604,"askPrice":0.55,"askSize":200000,"bidPrice":0.51,"bidSize":38000,"shortable":0,"etf":0,"ttmEps":-0.4781268969844319,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782955800000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":0.53,"openAndCloseTimeList":[[1782783000000,1782792000000],[1782795600000,1782806400000]],"volumeRatio":0.9546091178187551,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2647653191","title":"557个药品通过2026年基本医保药品目录初审，今年有哪些变化？","url":"https://stock-news.laohu8.com/highlight/detail?id=2647653191","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647653191?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:28","pubTimestamp":1782811680,"startTime":"0","endTime":"0","summary":"　　近日，国家医保局公布了通过初步形式审查的2026年基本医保药品目录和商保创新药目录名单，并对相关初审名单的药品信息进行了公示。　　此次药品目录调整共收到企业申报资料818份，涉及674个药品通用名，经审核，申请基本目录外375个通用名，通过初审334个；目录内229个通用名，通过初审223个。　　另国家医保局还特别提到，今年部分高价、或超出医保承载能力的药品通过目录形式初审，仅代表符合申报条件，可以进入下一流程。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxyy/2026-06-30/doc-inifesxw6661093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647582361","title":"轩竹生物-B：1类创新药安奈拉唑钠肠溶片新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2647582361","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647582361?lang=zh_cn&edition=full","pubTime":"2026-06-30 13:24","pubTimestamp":1782797040,"startTime":"0","endTime":"0","summary":"6月30日，轩竹生物-B（02575）发布公告，宣布自主研发的国家1类创新药安奈拉唑钠肠溶片（商品名：安久卫?）用于治疗成人反流性食管炎的新适应症上市申请已获国家药品监督管理局正式受理。此次受理基于在中国开展的多中心、随机、双盲双模拟、阳性药平行对照的III期注册临床研究结果，安奈拉唑钠60mg组治愈率为88.4%，而雷贝拉唑钠20mg组为84.6%，两组率差为3.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606303788166360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","IPOS","BK1574","BK1191","159992","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647358924","title":"【券商聚焦】国金证券：创新药企业扭亏节点已至 持续关注小核酸、双抗、ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2647358924","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647358924?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:13","pubTimestamp":1782789198,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。具体布局思路而言：(1)布局业绩财报窗口期，掘金业绩超预期标的；(2)关注学会大会动态，把握重磅临床数据发布窗口；(3)聚焦核心赛道，持续关注小核酸、双抗、ADC等相关标的的投资机会。风险提示：汇兑风险、投融资周期波动风险、并购整合不及预期的风险、数据安全与隐私合规风险等。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984822","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0201","BK4080","BK4231","BK0012","BK0028","ADC","BK0183","159992","06978","BK0188","BK1161","BK1574","BK0276","600109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647300001","title":"557个药品通过医保初审 创新药板块全线拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=2647300001","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647300001?lang=zh_cn&edition=full","pubTime":"2026-06-30 04:55","pubTimestamp":1782766500,"startTime":"0","endTime":"0","summary":"　　6月29日，国家医保局对通过2026年目录初审的药品名单和主要信息进行公示，其中557个、54个药品分别通过基本医保药品目录、商保创新药目录初步形式审查。　　受此消息提振，创新药板块全线拉升。　　据介绍，今年申报品种数量进一步增长，申报材料818份，涉及674个药品通用名，比2025年增加100份申报材料、41个药品通用名。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-06-30/doc-inifcmen6874404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372807","title":"多股涨停、ETF领跑、成交额翻倍，创新药能否“苦尽甘来”","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372807","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647372807?lang=zh_cn&edition=full","pubTime":"2026-06-29 21:08","pubTimestamp":1782738480,"startTime":"0","endTime":"0","summary":"当日恒生指数涨幅前五的主题指数全部聚焦创新药赛道，整体涨幅均超7%。成交数据显示，55只医药类ETF全天合计成交额突破89亿元，较前一交易日直接翻倍。细分来看，有16只ETF单日成交额超过1亿元，其中银华创新药ETF成交最为活跃，单日成交额达17.8亿元，环比增幅1.4倍；广发创新药ETF、易方达医药ETF单日成交额均超11亿元。广发、易方达旗下创新药ETF走势趋同，资金持续涌入，年内累计净流入金额均突破10亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-06-29/doc-inifauhu6991612.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-06-29/doc-inifauhu6991612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4550","06978","159992","BK1161","BK1574","BK4588","BK4585","FDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647034378","title":"动量资金大调仓，浮现新机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2647034378","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647034378?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:03","pubTimestamp":1782727380,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　周一A股市场出现宽幅震荡中强劲修复的态势。　　其中，科创50指数在早盘一度涨幅逾4%，但随后受阻回落，一度收出绿盘。不过，午市后，伴随半导体国产链方向龙头品种的强劲拉升，科创50指数再度走高，并以次高点收盘，大涨4.61%，再创历史新高。看来，短线A股热点结构出现了新的特征，有望催生新的交易性机会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-06-29/doc-inifapyw6983247.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-06-29/doc-inifapyw6983247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ARTY","CHAT","BK1574","SINA","BK1161","AIPO","06978","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647327350","title":"创新药支付变天，这些细分赛道或藏有重大机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2647327350","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647327350?lang=zh_cn&edition=full","pubTime":"2026-06-29 17:00","pubTimestamp":1782723601,"startTime":"0","endTime":"0","summary":"商保创新药目录的设立，试图打破这一僵局。与基本医保不同，商保目录不追求“最低价”，而是以“临床价值与成本效益匹配”为原则，为高价创新药提供支付通道。其中7款已在2025年商保目录中的药品，此次主动申报基本医保目录，侧面印证了商保支付路径的可行性。抓住细分赛道机遇在创新药产业进入兑现周期的背景下，细分赛道的投资机遇集中于技术迭代与全球化能力两个维度。ADC赛道已进入全球第一梯队。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202606/29/20260629625035.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202606/29/20260629625035.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260629/32293237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1161","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647321687","title":"一品红：痛风创新药AR882国内Ⅲ期临床试验完成全部患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2647321687","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647321687?lang=zh_cn&edition=full","pubTime":"2026-06-29 15:48","pubTimestamp":1782719291,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)06月29日在投资者关系平台上答复投资者关心的问题。投资者提问：疼风药国内第三期试验，之前不是说六月份结束吗，目前为何还没有通过出来？一品红回复：尊敬的投资者您好，感谢您对公司的关注。2025年11月，公司在研的痛风创新药AR882（氘泊替诺雷）国内Ⅲ期临床试验完成全部患者入组。目前，正在进行关键性Ⅲ期临床试验，试验进展顺利。此外，药品研发具有周期长、投入高、风险大等特点，敬请广大投资者谨慎决策，注意投资风险。祝您投资愉快。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900019343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","159992","BK1574","BK1161","06978","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647328114","title":"7款高价创新药有望降价","url":"https://stock-news.laohu8.com/highlight/detail?id=2647328114","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647328114?lang=zh_cn&edition=full","pubTime":"2026-06-29 12:53","pubTimestamp":1782708780,"startTime":"0","endTime":"0","summary":"　　6月29日，国家医保局公布了关于通过2026年国家基本医疗保险、生育保险和工伤保险药品目录及商保创新药目录调整初步形式审查的药品及相关信息。　　据第一财经记者梳理，有7款原本已在2025年商保目录的创新药，正在寻求进入新一轮基本医保目录，这些药已通过基本医保目录调整初步形式审查。　　已在商保目录中的创新药，若想顺利纳入基本医保目录，往往需要承受较大的价格降幅，这也考验药企进医保的决心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/2026-06-29/doc-iniezxce7125475.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/2026-06-29/doc-iniezxce7125475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647328051","title":"A股突变！一则利好，创新药全线拉升，涨停潮来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2647328051","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647328051?lang=zh_cn&edition=full","pubTime":"2026-06-29 12:29","pubTimestamp":1782707340,"startTime":"0","endTime":"0","summary":"　　6月29日上午，A股三大指数涨跌不一。截至午盘收盘，沪指涨0.17%，科创综指涨0.36%，深证成指跌1.21%，创业板指跌1.28%。　　盘面上，全市场超1900只个股上涨。创新药板块全面爆发，CRO概念板块飙涨7%；消费板块出现明显反弹，酒类、软饮料、食品等震荡拉升，生猪养殖板块持续活跃。　　港股医药股同步飙涨，药明康德、百济神州等头部企业均涨超5%。　　百济神州涨超10%，百利天恒均大涨12%，药明康德涨6%，恒瑞医药涨超8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-06-29/doc-iniezxay2310550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1161","159992","159982","BK1574","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647976340","title":"创新药概念强势拉升，我武生物大涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647976340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647976340?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:42","pubTimestamp":1782704521,"startTime":"0","endTime":"0","summary":"6月29日，创新药概念强势走高，我武生物盘中一度大涨超12%。中信证券指出，2026年以来，中国创新药BD交易金额超预期增长，产业全球竞争力进一步提升；国内市场快速放量，从2025年报来看，头部创新药企业在新产品驱动下，创新药收入快速增长，Biopharma陆续进入盈利拐点。中邮证券表示，预计我武生物26/27/28年收入分别为12.0/13.7/15.7亿元，同比增长13.3%/14.0%/14.5%；归母净利润为4.4/5.2/6.1亿元，同比增长16.6%/16.0%/17.6%，对应PE为27/23/19倍。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026062900013236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0028","300357","BK1574","06978","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647347933","title":"港股异动 | 创新药概念股全新爆发 超600个药品通过初审 “医保+商保”双目录谈判进入实质性阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2647347933","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647347933?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:53","pubTimestamp":1782701619,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647473833","title":"557个药品进医保初审！创新药集体走强，广生堂20CM涨停_手机新浪网","url":"https://stock-news.laohu8.com/highlight/detail?id=2647473833","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647473833?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:34","pubTimestamp":1782700447,"startTime":"0","endTime":"0","summary":"557个药品进医保初审！创新药集体走强，广生堂20CM涨停    分时图\r\n\r\n　　6月29日消息，创新药概念持续拉升，广生堂20cm涨停，新华制药、济民健康、太龙药业等多股涨停。\r\n\r\n　　消息面上，国家医保局6月29日对通过2026年目录初审的药品名单和主要信息进行公示，其中557个、54个药品分别通过基本医保药品目录、商保创新药目录初步形式审查。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202606/29/20260629618945.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202606/29/20260629618945.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260629/32292731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300436","06978","159992","SINA","BK1574","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647347358","title":"创新药板块逆市大涨！凯莱英、海南海药等近十只涨停，多股涨超10%！_手机新浪网","url":"https://stock-news.laohu8.com/highlight/detail?id=2647347358","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647347358?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:34","pubTimestamp":1782700446,"startTime":"0","endTime":"0","summary":"创新药板块逆市大涨！凯莱英、海南海药等近十只涨停，多股涨超10%！    分时图\r\n\r\n　　创新药板块逆市大涨，凯莱英、海南海药、太龙药业、新华制药、双鹭药业等近十只涨停，新赣江逼近涨停，三生国健、益方生物、睿智医药、佰仁医疗、艾迪药业、荣昌生物、舒泰神、圣诺生物、百利天恒涨超10%，赛升药业、诺思兰德、康龙化成、贝达药业、诺诚健华跟涨。\r\n\r\n　　消息面上，国家医保局6月29日对通过2026年目录初审的药品名单和主要信息进行公示，其中557个、54个药品分别通过基本医保药品目录、商保创新药目录初步形式审查。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202606/29/20260629655429.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202606/29/20260629655429.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260629/32292729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","BK0188","BK1161","06978","BK1574","159992","BK0132","000566","BK0239","BK0060","LU1328615791.USD","BK0146","SINA","BK0070","06821","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647478013","title":"快讯：科创50涨超3% 创新药板块短线拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=2647478013","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647478013?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:34","pubTimestamp":1782700444,"startTime":"0","endTime":"0","summary":"　　6月29日消息，指数冲高回落，创指涨幅收窄，此前一度涨超1%，科创50持续走强涨超3%.　　板块方面，半导体硅片板块延续强势，神工股份20cm涨停，沪硅产业涨超10%；存储芯片概念反复活跃，时空科技涨停，创历史新高；证券板块宽幅震荡多数上涨，招商证券领涨；早盘电子特气概念大幅高开，金宏气体涨超10%；创新药板块短线拉升，广生堂涨超15%。　　截至发稿，沪指报4030.04点，涨0.07%，深成指报15786.40点，涨0.03%，创指报4211.52点，涨0.41%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202606/29/20260629341183.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202606/29/20260629341183.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260629/32292724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06978","BK1161","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647475483","title":"创新药概念全线扬升 晶泰控股(02228)涨逾14% 机构指创新药仍为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2647475483","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647475483?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:33","pubTimestamp":1782700428,"startTime":"0","endTime":"0","summary":"消息面上，华鑫证券新近研究表示，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。以恒瑞医药为代表的创新药企业，创新药的收入比重持续提升。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984679","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","LU0072913022.USD","06855","LU1961090484.USD","LU0348825331.USD","LU1993786604.SGD","LU0417516902.SGD","LU0067412154.USD","01530","LU1328277881.USD","LU1969619763.USD","LU0348784397.USD","02228","LU0348766576.USD","HK0000165453.HKD","LU1226287529.USD","LU0540923850.HKD","09995","BK1574","02637","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0417516571.SGD","LU1226288253.USD","02162","LU1720050803.USD","LU0348767384.USD","LU0634319403.HKD","LU0315179316.USD","LU1960683339.HKD","LU1951186391.HKD","BK1141","06978","09969","LU2476274720.SGD","LU0348735423.USD","LU2476274308.USD","IE00BZ08YR35.GBP","159992","LU0348783233.USD","BK1583","LU0348827113.USD","LU0880133367.SGD","LU1008478684.HKD","01093","LU0326950275.SGD","LU1226287792.SGD","02157","09926","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647428083","title":"新股首日 | “肾病创新药第一股”礼邦医药(09637.HK)首挂上市 早盘涨近97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647428083","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647428083?lang=zh_cn&edition=full","pubTime":"2026-06-29 09:49","pubTimestamp":1782697754,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1515","06978","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646435928","title":"国产创新药出海交易高增，创新药ETF易方达（516080）连续5日“吸金”合计1.6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2646435928","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646435928?lang=zh_cn&edition=full","pubTime":"2026-06-26 18:45","pubTimestamp":1782470706,"startTime":"0","endTime":"0","summary":"截至收盘，恒生港股通创新药指数下跌1.1%，中证港股通医药卫生综合指数下跌1.2%，中证创新药产业指数下跌3.1%，中证生物科技主题指数下跌2.7%，沪深300医药卫生指数下跌1.9%。同花顺iFinD数据显示，截至昨日，创新药ETF易方达(516080，联接基金A/C：019666/019667)已连续5日获资金加码，合计达1.6亿元。消息面上，2026年一季度，国家药监局批准1类新药14个，其中国产新药12个；我国在研新药管线占全球30%，位列全球第二，同期创新药对外授权交易总额超600亿美元，接近去年全年交易额的一半。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026062600037705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","516080","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646543353","title":"白云山：当前公司创新药研发管线推进有序","url":"https://stock-news.laohu8.com/highlight/detail?id=2646543353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646543353?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:15","pubTimestamp":1782465313,"startTime":"0","endTime":"0","summary":"当前公司创新药研发管线推进有序，1类创新治疗领域涵盖慢性心力衰竭、妇科、抗感染、抗肿瘤、骨关节炎疾病等临床需求迫切的方向，着力满足未被充分满足的临床医疗需求，同时不断推进2类改良型新药研发工作。公司研发项目具体情况详见公司定期报告以及相关临时公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600031556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","06978","BK0239","BK0097","BK1191","BK0028","BK1521","00874","BK1197","600332","BK0096","BK0070","BK0196","BK1606","159992","BK0188","BK0183","BK0012","BK1161","BK1515","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646633473","title":"中国创新药抢占全球半壁江山：出海产业价值全面释放 高退货、低兑现、同质化困局显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2646633473","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646633473?lang=zh_cn&edition=full","pubTime":"2026-06-26 15:27","pubTimestamp":1782458820,"startTime":"0","endTime":"0","summary":"　　2025年，中国创新药海外BD交易总额定格在1357亿美元，同比增幅达161%，中国也首次超越美国，占据全球License-out总额的49%。从2020年全年30亿美元的起步规模，到2026年单季度突破600亿美元的交易体量，中国创新药资产的全球价值正在被快速重估。　　但在百亿级交易频出的行业狂欢背后，隐藏在公告数字里的高额水分、居高不下的历史退货率、同质化内卷下的定价权缺失，以及地缘政策的不确定性，也共同构成了出海浪潮下的挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-06-26/doc-inietnfw1966527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159992","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0182},{"period":"1month","weight":-0.3077},{"period":"3month","weight":-0.8029},{"period":"6month","weight":-0.8157},{"period":"1year","weight":-0.8078},{"period":"ytd","weight":-0.8157}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1073},{"period":"1year","weight":-0.0495},{"period":"ytd","weight":-0.1073}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.167652},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073624},{"month":6,"riseRate":0.666667,"avgChangeRate":0.015994},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}